Bioavailability of Ubiquinol in Huntington Disease

• Register: ClinicalTrials.gov
• Last refreshed on: 13 June 2016
• Main ID: NCT00980694
• Date of registration: 17/09/2009
• Prospective Registration: No
• Primary sponsor: University of Rochester
• Public title: Bioavailability of Ubiquinol in Huntington Disease
• Scientific title: Bioavailability of Ubiquinol in Huntington Disease
• Date of first enrolment: September 2009
• Target sample size: 6
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/show/NCT00980694
• Study type: Interventional
• Study design: Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label
• Phase: Phase 1

Countries of recruitment

United States

Contacts

• Name: Karl Kieburtz, MD
• Affiliation: University of Rochester

Key inclusion & exclusion criteria

Inclusion Criteria:

- Have manifest Huntington disease

- Be 18 years of age or older

- Be taking an oxidized formulation of CoQ for at least 30 days prior to the baseline
visit

- Be on a steady dose of all concomitant medications for at least 30 days prior to the
baseline visit

Exclusion Criteria:

- Have a history of intolerability of sensitivity to CoQ

- Have an unstable medical or psychiatric illness

- Be pregnant or breastfeeding; women of childbearing age must use reliable
contraception



Age minimum: 18 Years
Age maximum: N/A
Gender: Both

Health Condition(s) or Problem(s) studied

Huntington Disease

Intervention(s)

Dietary Supplement: ubiquinol

Primary Outcome(s)

serum coenzyme Q10 levels [Time Frame: 8 weeks]

Secondary ID(s)

UQ01

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

Kaneka Corporation